Statistiche di base
| CIK | 1596062 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Q BioMed Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| November 4, 2024 |
QBIO / Q BioMed Inc. / YA II PN, Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm2427411d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.4 TO SCHEDULE 13G Under the Securities Exchange Act of 1934 Q Biomed Inc. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) September 30, 2024 (Date of Event, which Requires Filing of this Statement) Check th |
|
| November 4, 2024 |
QBIO / Q BioMed Inc. / YA II PN, Ltd. - EXHIBIT 99.1 JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Q BioMed Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as ame |
|
| June 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55 |
|
| June 16, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5553 |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2023 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| May 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2023 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: November 30, 2022 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 M |
|
| January 3, 2023 |
EX-99.1 2 tm231355d5ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Q BioMed, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated unde |
|
| January 3, 2023 |
QBIO / Q BioMed Inc / YA II PN, Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO SCHEDULE 13G Under the Securities Exchange Act of 1934 Q Biomed, Inc. (Name of Issuer) Common Shares, with a par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) December 31, 2022 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Q BIOMED INC. (Name of Registrant |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement Q BIOMED INC. (Name of Registrant |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2022 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 18, 2022 |
Certificate of Designations for Series C Convertible Preferred Stock filed on November 16, 2022 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, POWERS, PREFERENCES AND OTHER RIGHTS OF PREFERRED STOCK AND QUALIFICATIONS, LIMITATIONS AND RESTRICTIONS THEREOF of SERIES C CONVERTIBLE PREFERRED STOCK of Q BIOMED INC. (Pursuant to Section 78.1955 of the Nevada Revised Statutes) Q BIOMED INC., a Nevada corporation (the ?Corporation?), pursuant to the provisions of Section 78.1955 of the Nevada Revised Sta |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: August 31, 2022 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 Mad |
|
| October 6, 2022 |
October 6, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Re: Q BioMed Inc. Registration Statement on Form S-1 (File No. 333-252003) Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ?Act?), Q BioMed Inc., a corporation organized under the laws of the State of Nevada (the ?Regi |
|
| July 28, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: May 31, 2022 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 Madiso |
|
| June 1, 2022 |
QBIO / Q BioMed Inc / Jatwes Ari - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Q BioMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) May 26, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 13, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2022 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2022 |
Exhibit 10.23 ? AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT ? THIS AGREEMENT (the ?Amended Agreement?), dated March 26, 2019, amends the Patent and Technology License and Purchase Option Agreement (the ?License Agreement?) entered into on October 29, 2015 by and between (i) Q BioMed Inc. (?Q Bio?) and (ii) Mannin Research Inc. (?Mannin?) (together, the ?Parties?). ? W |
|
| February 28, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| January 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 21, 2022 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 25, 2022 |
Conversion Agreement, dated January 21, 2022 Exhibit 10.1 Conversion Agreement This Conversion Agreement (this ?Agreement?) is made and entered into as of January 21, 2022, by and between Q Biomed Inc., a Nevada corporation (the ?Company?), and YA II PN, Ltd. (the ?Holder?), holder of the Company?s Convertible Debentures (the ?Debentures?). Recitals WHEREAS, on February 12, 2021, the Company entered into a securities purchase agreement (the |
|
| January 11, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Q BioMed, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as am |
|
| January 11, 2022 |
QBIO / Q BioMed Inc / YA II PN, Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO SCHEDULE 13G Under the Securities Exchange Act of 1934 Q Biomed, Inc. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 174736N105 (CUSIP Number) December 31, 2021 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 7, 2021 |
Securities Purchase Agreement, dated September 29, 2021 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 29, 2021, by and between Q BIOMED INC., a Nevada corporation, with headquarters located at 366 Madison Avenue, New Yok, NY 10022 (the ?Company?) and GS CAPITAL PARTNERS, LLC, a New York limited liability company, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 112 |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 7, 2021 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| October 7, 2021 |
Exhibit 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $2,200 |
|
| July 30, 2021 |
Securities Purchase Agreement, Dated July 26, 2021 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of July 26th, 2021 (the ?Effective Date?), by and between Q BIOMED, INC., a Nevada corporation, with headquarters located at c/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY 10017 (the ?Company?), and PLATINUM POINT CAPITAL LLC, a Nevada limited liability company, with it |
|
| July 30, 2021 |
Form of Convertible Promissory Note Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2021 Date of Report (Date of earliest event reported) Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 30, 2021 |
Amendment Agreement, Date July 22, 2021 Exhibit 10.4 AGREEMENT This Amendment Agreement (the ?Agreement?), dated as of July 22, 2021, is entered into by and between Q BIOMED INC., a company incorporated under the laws of the State of Nevada (the ?Company?) and YA II PN, Ltd. (the ?Buyer?), and amends the convertible debenture issued by the Company to the Buyer on December 23, 2020 (the ?Convertible Debenture?) issued pursuant to a Secur |
|
| July 30, 2021 |
Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"). THE HOLDER HEREOF, BY ACQUIRING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORAT |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Exact |
|
| May 10, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 5, 2021 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) c/o |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number 325-0101 Expires: July 31, 2023 Estimated average burden hours per response 1.00 FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing a |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (E |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2021 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| February 16, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of February 12, 2021, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, |
|
| February 16, 2021 |
Form of Debenture filed as Exhibit 10.2 to our current report on Form 8-k filed on February 16, 2021 Exhibit 10.2 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| February 5, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Q Biomed, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as am |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE 13G Under the Securities Exchange Act of 1934 Q Biomed, Inc. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) December 31, 2020 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 11, 2021 |
Exhibit 21.1 List of Subsidiaries Q BioMed Inc. has two subsidiaries over each of which it has 100% of the voting and dispositive control: (i) Q BioMed Cayman SEZC, which was incorporated in the Cayman Islands; and (ii) QBMG Q BioMed Germany UG, , which was incorporated in Germany. |
|
| January 11, 2021 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on January 8, 2021 Registration No. |
|
| December 29, 2020 |
Exhibit 10.4 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of October , 2020, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY 10017 (the "Company"), and each of the investors that has signed this Agreement (individually, a "Buyer" and collect |
|
| December 29, 2020 |
Exhibit 10.3 AGREEMENT This Agreement (the “Agreement”), dated as of December 23, 2020, is entered into by and between Q BIOMED INC., a company incorporated under the laws of the State of Nevada (the “Company”), and YA II PN, LTD. (the “Holder”). BACKGROUND (A) The Board of Directors of the Company has authorized the issuance of a series of preferred stock of the Company consisting of 1,000,000 sh |
|
| December 29, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 23, 2020, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, |
|
| December 29, 2020 |
Form of Debenture filed as Exhibit 10.2 to our current report on Form 8-k filed on December 29, 2020 Exhibit 10.2 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| December 29, 2020 |
Exhibit 10.5 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"). THE HOLDER HEREOF, BY ACQUIRING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORAT |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 23, 2020 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Exa |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Exact |
|
| June 11, 2020 |
QBIO / Q BioMed Inc. / Jatwes Ari - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Q BioMed Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) February 10, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 21, 2020 |
PROSPECTUS Filed Pursuant to Rule 424(B)(3) Registration No. 333-237872 1,836,286 Shares of Common Stock underlying shares of Series A Convertible Preferred Stock 3,163,714 Shares of Common Stock underlying shares of Series B Convertible Preferred Stock This prospectus relates to the offer and sale, from time to time, of up to 5,000,000 shares of common stock of Q BioMed Inc. (the “Company”, “we”, |
|
| May 6, 2020 |
United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| April 28, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on April 28, 2020 Registration No. |
|
| April 28, 2020 |
Exhibit 21.1 List of Subsidiaries Q BioMed Inc. has two subsidiaries over each of which it has 100% of the voting and dispositive control: (i) Q BioMed Cayman SEZC, which was incorporated in the Cayman Islands; and (ii) QBMG Q BioMed Germany UG, , which was incorporated in Germany. |
|
| April 20, 2020 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2020 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| April 13, 2020 |
QBIO / Q BioMed Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 29, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (E |
|
| April 8, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Q Biomed, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as am |
|
| April 8, 2020 |
QBIO / Q BioMed Inc. / YA GLOBAL MASTER SPV, LTD. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Q Biomed, Inc. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) 74736N105 (CUSIP Number) March 31, 2020 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 7, 2020 |
Exhibit 3.2 Business Entity - Filing Acknowledgement 04/06/2020 Work Order Item Number: W2020040600638-508494 Filing Number: 20200590772 Filing Type: Certificate of Designation Filing Date/Time: 4/6/2020 11:04:00 AM Filing Page(s): 13 Indexed Entity Information: Entity ID: E0565792013-4 Entity Name: Q BIOMED INC. Entity Status: Active Expiration Date: None Commercial Registered Agent NASCENT GROUP |
|
| April 7, 2020 |
Exhibit 3.1 Business Entity - Filing Acknowledgement 04/06/2020 Work Order Item Number: W2020040600629-508483 Filing Number: 20200590748 Filing Type: Certificate of Designation Filing Date/Time: 4/6/2020 11:03:00 AM Filing Page(s): 12 Indexed Entity Information: Entity ID: E0565792013-4 Entity Name: Q BIOMED INC. Entity Status: Active Expiration Date: None Commercial Registered Agent NASCENT GROUP |
|
| April 7, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 6, 2020, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the “Company”), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Buyer”). WITNESSETH WHE |
|
| April 7, 2020 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 6, 2020, by and among Q BIOMED INC., a Nevada corporation (the “Company”), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Investor”). WHEREAS: A. In connection with the Securities Purchase Agreement by and among the parties hereto of even date herewith (the “Se |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2020 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| April 7, 2020 |
Sets Roadmad to Uplisting and Provides Cash Runway to 2021 and Beyond Exhibit 99.1 Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a minimum of $3,800,000 of Debt Conversion Sets Roadmad to Uplisting and Provides Cash Runway to 2021 and Beyond NEW YORK, April 7, 2020 - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the entering of a significant financial transaction wi |
|
| March 19, 2020 |
QBIO / Q BioMed Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on March 19, 2020 Registration No. |
|
| March 19, 2020 |
QBIO / Q BioMed Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on March 19, 2020 Registration No. |
|
| February 28, 2020 |
Exhibit 4.4 DESCRIPTION OF SECURITIES As of February 26, 2020, Q BioMed Inc. (the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.001 per share (“common stock”). The following description of the Company’s common stock is a summary and is not complete. For a complete description, please refer to our ar |
|
| February 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ¨ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| February 21, 2020 |
Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain Exhibit 99.1 Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain ● First orders for product received, with initial doses to ship in February ● Full commercial production and availability starting in March NEW YORK, February 13, 2020 - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Ch |
|
| February 21, 2020 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 13, 2020 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| January 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 15, 2020 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| December 12, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December , 2019, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a |
|
| December 12, 2019 |
Exhibit 10.2 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| December 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| December 4, 2019 |
Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 27, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| November 20, 2019 |
Exhibit 99.1 Q BioMed Announces FDA Approval Company Gets Green Light for Manufacturing FDA Approved Non-Opioid Cancer Palliation Drug NEW YORK, Nov. 20, 2019 /PRNewswire/ - Q BioMed Inc. (QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP |
|
| November 20, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| October 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Exa |
|
| October 15, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 11, 2019, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, |
|
| October 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| October 15, 2019 |
Exhibit 10.2 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| September 26, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| September 10, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 5, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| September 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| September 6, 2019 |
Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE Effective Date: August 28, 2019 U.S. $550,000.00 FOR VALUE RECEIVED, Q BioMed Inc., a Nevada corporation (“Borrower”), promises to pay to Iliad Research and Trading, L.P., a Utah limited partnership, or its successors or assigns (“Lender”), $550,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve (12) months af |
|
| September 6, 2019 |
Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of August 28, 2019, is entered into by and between Q BioMed Inc., a Nevada corporation (“Company”), and Iliad Research and Trading, L.P., a Utah limited partnership, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in reliance upo |
|
| September 4, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2019 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| July 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Exact |
|
| July 16, 2019 |
QBIO / Q BioMed Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: May 31, 2019 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 Madiso |
|
| April 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC |
|
| April 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: February 28, 2019 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 M |
|
| March 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2018 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| March 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: November 30, 2018 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 366 M |
|
| January 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| December 26, 2018 |
Q BioMed Inc. c/o Ortoli Rosenstadt LLP 366 Madison Avenue – 3rd Floor New York, NY 10017 Telephone: 212-588-0022 Fax: 212-826-9307 December 26, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Q BioMed Inc. (the “Company) Registration Statement on Form S-1 File No. 333-227998 (the “Registration Statement |
|
| December 21, 2018 |
Q BioMed Inc. c/o Ortoli Rosenstadt LLP 366 Madison Avenue – 3rd Floor New York, NY 10017 Telephone: 212-588-0022 Fax: 212-826-9307 December 21, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Q BioMed Inc. (the “Company) Registration Statement on Form S-1 File No. 333-227998 (the “Registration Statement |
|
| December 13, 2018 |
QBIO / Q BioMed Inc. FORM S-1/A As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. |
|
| November 28, 2018 |
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare Exhibit 99.1 Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare Strategic Acquisition Gives Company Ownership of Brand Name Drug and Related Market Authorizations in 22 Countries in Which Metastron™ is Already Registered and Approved for Sale Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreemen |
|
| November 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 23, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| November 28, 2018 |
Exhibit 10.1 Dated 23 November 2018 GE HEALTHCARE LIMITED and Q BIOMED, INC ASSET SALE AGREEMENT THIS ASSET SALE AGREEMENT (the "Agreement") is dated 23 November 2018 Parties (1) GE HEALTHCARE LIMITED incorporated and registered in England and Wales with company number 01002610 whose registered office is at Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA (the “Seller”). (2) Q BIOMED, INC |
|
| November 28, 2018 |
November 28, 2018 J. Nolan McWilliams Tonya Aldave U.S. Securities and Exchange Commission Washington, D.C. 20549 Via EDGAR Re: Q BioMed Inc. Registration Statement on Form S-1 Filed October 25, 2018 File No. 333-227998 Dear Mr. McWilliams and Ms. Aldave: This letter is in response to your letter of November 21, 2018 in which you provided a comment on the Registration Statement on Form S-1 (the “R |
|
| November 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No |
|
| October 25, 2018 |
As filed with the Securities and Exchange Commission on October 25, 2018 Registration No. |
|
| October 19, 2018 |
QBIO / Q BioMed Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- |
|
| October 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| September 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| September 24, 2018 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 21, 2018, is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor, New York, NY, 10022 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually |
|
| September 24, 2018 |
Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000 Exhibit 99.1 Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000 Sep 24, 2018 Financing Provides Necessary Capital to Reach Important Milestones NEW YORK, September 24, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global (‘Yorkville‘) for $4,000,000. Q BioMed has closed on |
|
| September 24, 2018 |
Exhibit 10.3 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| September 24, 2018 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 21, 2018, by and among Q BIOMED INC., a Nevada corporation (the “Company”), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Investor”). WHEREAS: A. In connection with the Securities Purchase Agreement by and among the parties hereto of even date herewith (th |
|
| July 18, 2018 |
QBIO / Q BioMed Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. ( |
|
| July 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Ex |
|
| June 8, 2018 |
QBIO / Q BioMed Inc. PRIMARY DOCUMENT UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D. |
|
| April 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC |
|
| February 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2017 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| February 20, 2018 |
Blueprint Q BioMed: Former Novartis Global Head and WuXi STA's VP of Pharmaceutical Development Joins Company Board NEW YORK, February 13, 2018 /PRNewswire/ ? Q BioMed Inc. |
|
| February 20, 2018 |
Non-qualified Stock Option Agreement Blueprint Non-qualified Stock Option Agreement This Incentive Stock Option Agreement (this ?Agreement?) is made and entered into as of February 12, 2018 by and between (i) Q BioMed Inc. |
|
| February 20, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 13, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identi |
|
| February 2, 2018 |
Q BioMed Inc. Prices $5.5 Million Public Offering Blueprint Q BioMed Inc. Prices $5.5 Million Public Offering Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018 NEW YORK, January 30, 2018 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,87 |
|
| February 2, 2018 |
Q Biomed Inc. Closes $5.48 Million Public Offering Blueprint Q Biomed Inc. Closes $5.48 Million Public Offering Company Expects Commercialization and Revenue from its Non-Opioid Pain Palliation Drug in Q2 2018 and Initiation of Multiple Pivotal Clinical Programs in 2018 NEW YORK, February 1, 2018 /PRNewswire/ ? Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce the closing of its |
|
| February 2, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 29, 2018 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identif |
|
| January 31, 2018 |
1,711,875 Shares of Common Stock 1,711,875 Warrants to Purchase Shares of Common Stock Untitled Document PROSPECTUS Filed Pursuant to Rule 424(b)(3) File No. 333-222008 1,711,875 Shares of Common Stock 1,711,875 Warrants to Purchase Shares of Common Stock We are offering 1,711,875 shares of our common stock and 1,711,875 warrants to purchase a share of our common stock. Each share of common stock is being sold together with a warrant to purchase up to one share of our common stock o |
|
| January 12, 2018 |
Form of Q BIOMED INC. [*] Share of Common Stock and One Warrant to Purchase [*] Share of Common Stock PLACEMENT AGENT AGREEMENT , 2018 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Ladies and Gentlemen: Subject to the terms and conditions herein (this ?Agreement?), Q BioMed Inc., a Nevada corporation (the ?Company?), hereby agrees to sell registered securities of the Co |
|
| January 12, 2018 |
Blueprint Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 January 12, 2018 Securities and Exchange Commission 100 F Street, N. |
|
| January 12, 2018 |
Blueprint Q BioMed Inc. c/o Ortoli Rosenstadt LLP 501 Madison Avenue ? 14th Floor New York, NY 10022 Telephone: 212-588-0022 Fax: 212-826-9307 January 12, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Q BioMed Inc. (the ?Company) Registration Statement on Form S-1 File No. 333-222008 (the ?Registration |
|
| January 12, 2018 |
As filed with the Securities and Exchange Commission on January 12, 2018 As filed with the Securities and Exchange Commission on January 12, 2018 Registration No. |
|
| January 12, 2018 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of , 2018, is by and among Q BioMed Inc. |
|
| January 10, 2018 |
As filed with the Securities and Exchange Commission on January 10, 2018 As filed with the Securities and Exchange Commission on January 10, 2018 Registration No. |
|
| January 10, 2018 |
Form of Q BIOMED INC. [*] Share of Common Stock and One Warrant to Purchase [*] Share of Common Stock PLACEMENT AGENT AGREEMENT , 2018 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Ladies and Gentlemen: Subject to the terms and conditions herein (this ?Agreement?), Q BioMed Inc., a Nevada corporation (the ?Company?), hereby agrees to sell registered securities of the Co |
|
| January 10, 2018 |
EX-10.17 5 spa.htm MATERIAL CONTRACTS SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of , 2018, is by and among Q BioMed Inc., a Nevada corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer desire to enter |
|
| January 10, 2018 |
COMMON STOCK PURCHASE WARRANT Q BIOMED INC. Warrant Shares: Initial Exercise Date: , 2018 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2018 (the ?Initial Exercise Date?) and on or prior to |
|
| December 22, 2017 |
As filed with the Securities and Exchange Commission on December 22, 2017 As filed with the Securities and Exchange Commission on December 22, 2017 Registration No. |
|
| December 12, 2017 |
As filed with the Securities and Exchange Commission on December 12, 2017 As filed with the Securities and Exchange Commission on December 12, 2017 Registration No. |
|
| December 5, 2017 |
QBIO / Q BioMed Inc. PRIMARY DOCUMENT (Current Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 000-55535 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identifi |
|
| December 5, 2017 |
Q BioMed Announces Full Settlement of All Convertible Debt Blueprint Q BioMed Announces Full Settlement of All Convertible Debt Company Closes Financial Year End With No Outstanding Convertible or Loan Debt NEW YORK, December 5, 2017 ? Q BioMed Inc. |
|
| October 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. |
|
| October 16, 2017 |
Q BioMed NOTIFICATION OF LATE FILING U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ?Form 10-K ?Form 20-F ?Form 11-K ? Form 10-Q ?Form 10-D ?Form N-SAR ?Form N-CSR For Period Ending: August 31, 2017 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 501 Madison Avenue, 14t |
|
| October 6, 2017 |
953,249 shares of Common Stock and up to 953,249 shares of Common Stock underlying the Warrants PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated September 26, 2017) Filed Pursuant to Rule 424(b)(3) Registration No. 333-220328 953,249 shares of Common Stock and up to 953,249 shares of Common Stock underlying the Warrants This prospectus supplement supplements the prospectus dated September 26, 2017 (the ?Prospectus?) of Q BioMed Inc. (the ?Company?, ?we?, ?us? and ?our?), which is part of a r |
|
| October 6, 2017 |
1,775,000 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated April 6, 2017) Filed Pursuant to Rule 424(b)(3) Registration No. 333-216618 1,775,000 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 6, 2017 (the “Prospectus”) of Q BioMed Inc. (the “Company”, “we”, “us’ and “our”), which is part of a registration statement on Form S-1 (File No. 333-216618) filed with the Un |
|
| October 4, 2017 |
953,249 shares of Common Stock and up to 953,249 shares of Common Stock underlying the Warrants PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 220328 953,249 shares of Common Stock and up to 953,249 shares of Common Stock underlying the Warrants This prospectus relates to the offer and sale, from time to time, of up to 1,906,498 shares of common stock of Q BioMed Inc. (the ?Company?, ?we?, ?us? and ?our?) by those stockholders named in the section of this prospectus entitled ?S |
|
| September 21, 2017 |
Q BioMed Inc. c/o Ortoli Rosenstadt LLP 501 Madison Avenue ? 14th Floor New York, NY 10022 Telephone: 212-588-0022 Fax: 212-826-9307 September 21, 2017 VIA EDGAR Mr. Chris Edwards U.S. Securities and Exchange Commission Division of Corporation Finance Re: Q BioMed Inc. (the ?Registrant?) Registration Statement on Form S-1 (the ?Registration Statement?) File No. 333-220328 Request for Acceleration |
|
| September 1, 2017 |
As filed with the Securities and Exchange Commission on September 1, 2017 As filed with the Securities and Exchange Commission on September 1, 2017 Registration No. |
|
| August 2, 2017 |
Q BIOMED INC. CLOSES $3,050,390 EQUITY FINANCING Exhibit 99.1 Q BIOMED INC. CLOSES $3,050,390 EQUITY FINANCING Funding Provides Capital to Meet Near Term Milestones and Catalysts Q BioMed Inc. (QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, in |
|
| August 2, 2017 |
Exhibit 10.4 PLACEMENT AGENCY AGREEMENT June 5, 2017 Brookline Capital Markets, a division of CIM Securities, LLC 509 Madison Avenue, Suite 1006 New York, New York 10022 Attention: William B. Buchanan, Jr., Managing Director Dear Mr. Buchanan: Q BIOMED, Inc., a Nevada corporation (“ Company”), the common stock of which is traded on the OTCQB under the trading symbol “QBIO,” hereby confirms its agr |
|
| August 2, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this " Agreement"), dated as of [-], is between Q BIOMED INC., a company incorporated under the laws of the State of Nevada, with headquarters located at 501 Madison Ave, 14 th Floor, New York, NY, 10022 (the " Company"), and each of the investors that has signed this Agreement (individually, a " Buyer" and collectively |
|
| August 2, 2017 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “ Agreement”), dated as of [-], by and among Q BIOMED INC., a Nevada corporation (the “ Company”), each of the investors that has signed this Agreement (individually, an “ Investor” and collectively the “ Investors”). WHEREAS: A. In connection with the Securities Purchase Agreement by and among the parties hereto o |
|
| August 2, 2017 |
Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"). THE HOLDER HEREOF, BY ACQUIRING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORAT |
|
| August 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| July 25, 2017 |
Q BIOMED INC. FINALIZES LICENSE AGREEMENT WITH OKLAHOMA MEDICAL RESEARCH FOUNDATION AND THE RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY FOR NOVEL LIVER CANCER TREATMENT June 15, 2017 NEW YORK, June 15, 2017 /PRNewswire/ ? Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotec |
|
| July 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| July 25, 2017 |
Q BIOMED INC. TO PRESENT AT THE SIXTH ANNUAL MARCUM MICROCAP CONFERENCE IN NEW YORK Q BIOMED INC. TO PRESENT AT THE SIXTH ANNUAL MARCUM MICROCAP CONFERENCE IN NEW YORK June 14, 2017 Company To Present at 9:30am ET June 15th 2017 at the Grand Hyatt NEW YORK, June 14 2017 ? Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at |
|
| July 25, 2017 |
TECHNOLOGY LICENSE AGREEMENT BETWEEN OMRF, RGCB AND QBIOMED TECHNOLOGY LICENSE AGREEMENT BETWEEN OMRF, RGCB AND QBIOMED This Technology License Agreement (?Agreement?) is by and between the Rajiv Gandhi Center for Biotechnology, an autonomous research institute under the Govt. |
|
| July 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. ( |
|
| July 19, 2017 |
Q BioMed QUARTERLY REPORT ON FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC. (Ex |
|
| July 18, 2017 |
Q BioMed NOTIFICATION OF LATE FILING FOR FORM 10-Q QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-55535 ?Form 10-K ?Form 20-F ?Form 11-K ? Form 10-Q ?Form 10-D ?Form N-SAR ?Form N-CSR For Period Ending: May 31, 2017 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Ortoli Rosenstadt LLP 501 Madison Avenue, New Yo |
|
| June 15, 2017 |
Q BIOMED INC. FINALIZES LICENSE AGREEMENT WITH OKLAHOMA MEDICAL RESEARCH FOUNDATION AND THE RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY FOR NOVEL LIVER CANCER TREATMENT June 15, 2017 NEW YORK, June 15, 2017 /PRNewswire/ ? Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotec |
|
| June 15, 2017 |
TECHNOLOGY LICENSE AGREEMENT BETWEEN OMRF, RGCB AND QBIOMED This Technology License Agreement (?Agreement?) is by and between the Rajiv Gandhi Center for Biotechnology, an autonomous research institute under the Govt. |
|
| June 15, 2017 |
Q BioMed CURRENT REPORT ON FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| June 15, 2017 |
Q BIOMED INC. TO PRESENT AT THE SIXTH ANNUAL MARCUM MICROCAP CONFERENCE IN NEW YORK Q BIOMED INC. TO PRESENT AT THE SIXTH ANNUAL MARCUM MICROCAP CONFERENCE IN NEW YORK June 14, 2017 Company To Present at 9:30am ET June 15th 2017 at the Grand Hyatt NEW YORK, June 14 2017 ? Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at |
|
| June 9, 2017 |
Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"). THE HOLDER HEREOF, BY ACQUIRING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATI |
|
| June 9, 2017 |
Exhibit 4.1 Non-qualified Stock Option Agreement This Incentive Stock Option Agreement (this “Agreement”) is made and entered into as of by and between (i) Q BioMed Inc. (the “Company”) on behalf of its Subsidiary Q BioMed Cayman SEZC (the “Subsidiary”) and (ii) Denis Corin (the “Participant”). Grant Date: Date of Agreement Exercise Price per Share: [] Number of Option Shares: 150,000 Expiration D |
|
| June 9, 2017 |
Q BIOMED INC ANNOUNCES COMMERCIALIZATION OF NON-NARCOTIC METASTATIC CANCER PAIN DRUG Exhibit 99.1 Q BIOMED INC ANNOUNCES COMMERCIALIZATION OF NON-NARCOTIC METASTATIC CANCER PAIN DRUG June 7, 2017 News COMPANY EXPECTS REVENUE FROM BONE PAIN DRUG AHEAD OF SCHEDULE NEW YORK, June 7, 2017 ? Q BioMed Inc. (OTCQB: QBIO), is very pleased to announce that the company has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastati |
|
| June 9, 2017 |
Exhibit 10.1 EXECUTIVE SERVICES AGREEMENT Executive Services Agreement dated as of June 1, 2017 by and among Q BioMed Cayman SEZC (?Company?), and Denis Corin (the ?Executive?). W I T N E S S E T H: The Company desire to engage the services of the Executive for purposes of general corporate management and development and more specifically for those services set forth below (collectively, the ?Exec |
|
| June 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) c |
|
| May 1, 2017 |
1,775,000 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated April 6, 2017) Filed Pursuant to Rule 424(b)(3) Registration No. 333-216618 1,775,000 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 6, 2017 (the ?Prospectus?) of Q BioMed Inc. (the ?Company?, ?we?, ?us? and ?our?), which is part of a registration statement on Form S-1 (File No. 333-216618) filed with the Un |
|
| April 25, 2017 |
Q Biomed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder Q Biomed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder New Treatment in Development Looks to Treat Rare Condition that Robs Approximately 20,000 US Children per Year of their Ability to Speak NEW YORK, April 25, 2017 ? Q BioMed Inc. |
|
| April 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| April 25, 2017 |
License Agreement on Patent & Know-How/Technology Effective Date: April 21, 2017 Licensor: ASDERA Licensee: QBioMed Inc (?Licensee?) and/or Q BioMed (Cayman) SEZC, as the case may be Licensor and Licensee are each, individually, a ?Party? and collectively the Parties License Agreement: This License Agreement (this ?Agreement?) grants Licensee the exclusive global license under the Patent Rights and the Know-How subject to the terms and conditions outlined in herein. |
|
| April 21, 2017 |
Q BioMed FIRST AMENDMENT TO QUARTERLY REPORT ON FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED I |
|
| April 14, 2017 |
Q BioMed QUARTERLY REPORT ON FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIOMED INC |
|
| April 10, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 7, 2017 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| April 10, 2017 |
Q BioMed Inc. Completes Final Closing on $4,000,000 Funding Exhibit 99.1 Q BioMed Inc. Completes Final Closing on $4,000,000 Funding NEW YORK, April 10, 2017 /PRNewswire/ - Q BioMed Inc. ( QBIO ) has closed on its final tranche of the $4,000,000 funding announced on November 30th, 2016. The company received $1,500,000 less fees on the final closing, bringing the total gross funds received to date to $4MM. Capital from the transaction will be used to advanc |
|
| April 7, 2017 |
1,775,000 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-216618 1,775,000 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, of up to 1,775,000 shares of the common stock of Q BioMed Inc. (the ?Company?, ?we?, ?us? and ?our?) by those stockholders named in the section of this prospectus entitled ?Selling Stockholders?. The shares of common stock being |
|
| March 31, 2017 |
FIRST AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT FIRST AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT THIS AGREEMENT (the ?Amended Agreement?), dated September 6, 2016, amends the Patent and Technology License and Purchase Option Agreement (the ?License Agreement?) entered into on May 30, 2016 by and between (i) Q BioMed Inc. |
|
| March 31, 2017 |
PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT This Patent and Technology License and Purchase Option Agreement is entered into on June 20, 2016 (? Signing Date?) by and between (i) Q BioMed Inc. |
|
| March 31, 2017 |
Q BioMed AMENDMENT TO QUARTERLY REPORT ON FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- |
|
| March 10, 2017 |
March 10, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Re: Q BioMed Inc. Registration Statement on Form S-1 (File No. 333-215240) Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ?Act?), Q BioMed Inc., a corporation organized under the laws of the State of Nevada (the ?Regis |
|
| March 10, 2017 |
As filed with the Securities and Exchange Commission on March 10, 2017 As filed with the Securities and Exchange Commission on March 10, 2017 Registration No. |
|
| March 10, 2017 |
SUPPLEMENT AND AMENDMENT AGREEMENT SUPPLEMENT AND AMENDMENT AGREEMENT This Supplement and Amendment Agreement (the ?Agreement?), dated as of March 8, 2017, is entered into by and between Q Biomed Inc. |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2016 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number : 000-55535 Q BIOMED INC. |
|
| February 15, 2017 |
QBIO / Q BioMed Inc. / LINDSAY ALAN P - LINDSAY 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) Q BioMed Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 74736N105 (CUSIP Number) August 10, 2015 (Date of Event which Requires Filing |
|
| December 22, 2016 |
As filed with the Securities and Exchange Commission on December 21, 2016 As filed with the Securities and Exchange Commission on December 21, 2016 Registration No. |
|
| November 30, 2016 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ? Agreement?), dated as of November , 2016, by and among Q BIOMED INC. |
|
| November 30, 2016 |
Q BIOMED INC. Secured Convertible Debenture NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. |
|
| November 30, 2016 |
SECURITY AGREEMENT (in favor of YA II CD, Ltd.) SECURITY AGREEMENT (in favor of YA II CD, Ltd.) THIS SECURITY AGREEMENT (the ? Agreement?) is entered into as of November , 2016 by and among (i) Q Biomed Inc., a Nevada corporation (the ? Issuer?), and (ii) any subsidiary and affiliate of the Issuer listed on Schedule 1 attached hereto either now or joined in the future (the ? Subsidiaries?; and jointly, severally, and collectively with the Issue |
|
| November 30, 2016 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement”), dated as of November , 2016, is between Q BIOMED INC. |
|
| November 30, 2016 |
Q BIOMED INC. ANNOUNCES ENTRY INTO DEFINITIVE FUNDING AGREEMENT FOR UP TO $4,000,000 Q BIOMED INC. ANNOUNCES ENTRY INTO DEFINITIVE FUNDING AGREEMENT FOR UP TO $4,000,000 Capital injection provides runway to bring FDA approved cancer palliation drug to market in early 2017 and continue advancing our glaucoma drug. NEW YORK, November 30, 2016 ? Q BioMed Inc. (OTCQB: QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global (?Yorkvil |
|
| November 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2016 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification N |
|
| October 17, 2016 |
exhibit10-1.htm EXHIBIT 10.1 PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT This Patent and Technology License and Purchase Option Agreement is entered into on June 20, 2016 (?Signing Date?) by and between (i) Q BioMed Inc. (?Q Bio?) and (ii) Bio-Nucleonics Inc. (?BNI?): BNI and Q Bio are hereinafter also referred to individually as a ?Party? and collectively as the ?Parties.? WHEREAS |
|
| October 17, 2016 |
exhibit10-2.htm EXHIBIT 10.2 FIRST AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT THIS AGREEMENT (the “Amended Agreement”), dated September , 2015, amends the Patent and Technology License and Purchase Option Agreement (the “License Agreement”) entered into on May 30, 2016 by and between (i) Q BioMed Inc. (“Q Bio”) and (ii) Bio-Nucleonics Inc. (“BNI”) (together, the “Part |
|
| October 17, 2016 |
form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2016 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q |
|
| September 7, 2016 |
Entry into a Material Definitive Agreement form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 7, 2016 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Iden |
|
| July 7, 2016 |
form10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2016 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55535 Q BIO |
|
| April 25, 2016 |
Q BioMed /A (Quarterly Report) form10-qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 29, 2016 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-19 |
|
| April 22, 2016 |
form10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 29, 2016 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-193328 |
|
| April 14, 2016 |
formnt10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-27239 ?Form 10-K ?Form 20-F ?Form 11-K ? Form 10-Q ?Form 10-D ?Form N-SAR ?Form N-CSR For Period Ending: February 29, 2016 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: c/o Sanders Ortoli Vaughn-Flam R |
|
| March 15, 2016 |
form10-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 333 |
|
| March 11, 2016 |
form10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 333-193328 Q BIOMED INC. |
|
| March 11, 2016 |
Exhibit 10.1 PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENT This Patent and Technology License and Purchase Option Agreement is entered into on October [-], 2015 (“Signing Date”) by and between (i) Q BioMed Inc. (“Q Bio”) and (ii) Mannin Research Inc. (“Mannin”): Mannin and Q Bio are hereinafter also referred to individually as a “Party” and collectively as the “Parties.” WHEREAS, Man |
|
| February 29, 2016 |
formnt10-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-27239 ?Form 10-K ?Form 20-F ?Form 11-K ?Form 10-Q ?Form 10-D ?Form N-SAR ?Form N-CSR For Period Ending: November 30, 2015 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: 501 Madison Avenue, New York, NY |
|
| January 13, 2016 |
exhibit10-7.htm Exhibit 10.7 CONSULTING AGREEMENT Consulting Agreement dated as of November 13, 2015 by and among Q BioMed Inc., (“Company”), and Pharmafor Ltd (the “Consultant”). W I T N E S S E T H: The Company desires to engage the services of the Consultant for purposes of technology assessment and product development and more specifically for those services set forth below (collectively, the |
|
| January 13, 2016 |
exhibit10-4.htm Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT |
|
| January 13, 2016 |
exhibit10-6.htm Exhibit 10.6 ADVISORY AGREEMENT Advisory Agreement dated as of June 1, 2105 by and among ISMO Tech Solutions, Inc. (?Company?), and Ari Jatwes or his incorporated company (the ?Advisor?). W I T N E S S E T H: The Company desire to engage the services of the Advisor for purposes of general business analysis and development and more specifically for those services set forth below (co |
|
| January 13, 2016 |
exhibit10-5.htm Exhibit 10.5 SCIENTIFIC ADVISORY AGREEMENT Scientific Advisory Agreement dated as of September 8, 2015 by and among Q BioMed Inc., a Nevada corporation (“Company”), and Wombat Capital Ltd., a limited corporation incorporated in the state of New York (the “Scientific Advisor”). W I T N E S S E T H: The Company desires to engage the services of the Scientific Advisor on a non-exclusi |
|
| January 13, 2016 |
exhibit10-1.htm Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT |
|
| January 13, 2016 |
EX-10.2 3 exhibit10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 8, 2016 by and between Q BioMed, Inc., a Nevada corporation, with headquarters located at 501 Madison Avenue 14th Floor New York, NY 10022 (the “Company”), and CMGT, Inc., a Cayman limited company, , with its address at 10 Market Street, #784 George Town, G |
|
| January 13, 2016 |
exhibit10-8.htm Exhibit 10.8 This Board of Directors Services Agreement (the ?Agreement?), dated June 5, 2015, is entered into between ISMO Tech Solutions, Inc., a Nevada corporation (?the Company), and William S. Rosenstadt, an individual with a principal place of residence in New York (?Director?). WHEREAS, the Company desires to retain the services of Director for the benefit of the Company and |
|
| January 13, 2016 |
form8-k.htm UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 8, 2016 Date of Report (Date of earliest event reported) Q BIOMED INC. (Exact name of registrant as specified in its charter) (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State |
|
| January 13, 2016 |
exhibit10-3.htm Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of , 2015 by and between Q BioMed, Inc., a Nevada corporation, with headquarters located at 501 Madison Avenue 14th Floor New York, NY 10022 (the “Company”), and , with its address at (the “Buyer”). The Company is defined as “the Borrower” and the Buyer is defined as “the Lende |
|
| October 30, 2015 |
form8-a12.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT 1934 Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 46-4013793 (State of Incorporation) (I.R.S. Employer Identification No.) c/o Sanders Ortoli Vaughn-Flam Rosens |
|
| October 29, 2015 |
exhibit.htm EXHIBIT 3.1 Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock) 1. Name of corporation: Q BioMed Inc. 2. The articles have been amended as follows: (provide article numbers, if available) Article 5 shall be replaced in its entirety to read: ?5. Authorized Shares: The aggregate number of share |
|
| October 29, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2015 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Ident |
|
| October 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2015 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-193328 Q BIOMED IN |
|
| October 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2015 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-193328 Q BIOMED INC. |
|
| October 15, 2015 |
formnt10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-27239 ?Form 10-K ?Form 20-F ?Form 11-K ? Form 10-Q ?Form 10-D ?Form N-SAR ?Form N-CSR For Period Ending: August 31, 2015 PART I: REGISTRANT INFORMATION Full Name of Registrant: Q BioMed Inc. Address of Principal Executive Office: 501 Madison Avenue, New York, NY 1 |
|
| October 9, 2015 |
Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 exhbit16-1.htm EXHIBIT 16.1 Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 October 8, 2015 Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549 Re: Q BioMed Inc. We have read Q BioMed Inc.?s statements included under Item 4.01 of its Form 8-K dated October 8, 2015 and agree with such statements, insofar as they apply to Weinberg & Baer LLC. Ver |
|
| October 9, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 8, 2014 Date of Report Q BIOMED INC. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Iden |
|
| October 9, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 8, 2014 Date of Report Q BIOMED INC. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identi |
|
| October 9, 2015 |
Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 exhibit16-1.htm EXHIBIT 16.1 Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 October 8, 2015 Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549 Re: Q BioMed Inc. We have read Q BioMed Inc.?s statements included under Item 4.01 of its Form 8-K dated October 8, 2015 and agree with such statements, insofar as they apply to Weinberg & Baer LLC. Ve |
|
| August 3, 2015 |
exhibit99-1.htm Exhibit 99.1 July 23, 2015 Denis Corin President Q BioMed Inc. c/o Sanders Ortoli Vaughn-Flam Rosenstadt LLP 501 Madison Avenue New York, NY 10022 Effective Immediately, I am resigning from the Board of Directors of Q BioMed Inc. as well as from all positions that I hold with the Q BioMed Inc. as an officer. My resignations do not arise from any dispute or disagreement with Q BioMe |
|
| August 3, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 20, 2015 Date of Report Q BioMed Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identifi |
|
| August 3, 2015 |
exhibit3-1.htm Exhibit 3.1 Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock) 1. Name of corporation: ISMO Tech Solutions, Inc. 2. The articles have been amended as follows: (provide article numbers, if available) Article 1 shall be replaced in its entirety to read: "1. Name of Company: The complete nam |
|
| July 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2015 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-193328 ISMO |
|
| June 29, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2015 Date of Report ISMO Tech Solutions, Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| June 16, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2015 Date of Report ISMO Tech Solutions, Inc. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employ |
|
| June 16, 2015 |
exhibit10-1.htm EXHIBIT 10.1 ADVISORY AGREEMENT Advisory Agreement dated as of June 1, 2105 by and among ISMO Tech Solutions, Inc. (?Company?), and Ari Jatwes or his incorporated company (the ?Advisor?). W I T N E S S E T H: The Company desire to engage the services of the Advisor for purposes of general business analysis and development and more specifically for those services set forth below (co |
|
| April 30, 2015 |
exhibit10-1.htm EXHIBIT 10.1 ADVISORY AGREEMENT Advisory Agreement dated as of April 21, 2105 by and among ISMO Tech Solutions Inc. (?Company?), and Denis Corin or his incorporated company (the ?Advisor?). W I T N E S S E T H: The Company desire to engage the services of the Advisor for purposes of general corporate development and more specifically for those services set forth below (collectively |
|
| April 30, 2015 |
form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 2015 Date of Report ISMO TECH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 333-193328 46-4013793 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| April 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2015 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54877 I |
|
| February 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended November 30, 2014 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number: 333-193328 ISMO TECH SO |
|
| October 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2014 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54877 ISM |
|
| July 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2014 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54877 ISMO T |
|
| April 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2014 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54877 I |
|
| April 1, 2014 |
Tech solutions, inc. 2,500,000 shares of common stock $0.02 per share Prospectus Filed Pursuant to Rule 424(b)(2) Registration No. 333-193328 Tech solutions, inc. 2,500,000 shares of common stock $0.02 per share ISMO Tech Solutions, Inc. is offering on a best-efforts basis a minimum of 1,250,000 and up to 2,500,000 shares of common stock at a fixed offering price of $0.02 per share. The shares are intended to be sold directly through the efforts of our sole officer |
|
| March 20, 2014 |
March 20, 2014 To: Barbara C. Jacobs, Assistant Director Or Jeff Kauten, Attorney-Advisor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: ISMO Tech Solutions, Inc. Registration Statement on Form S-1, and subsequent amendments thereto File No.: 333-193328 Dear Ms. Jacobs: I, Enrique Navas, am the President of ISMO Tech Sol |
|
| March 17, 2014 |
Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 Mr. |
|
| March 17, 2014 |
March 17, 2014 To: Barbara C. Jacobs, Assistant Director Or Jeff Kauten, Attorney-Advisor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: ISMO Tech Solutions, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed February 11, 2014 File No.: 333-193328 Dear Ms. Jacobs: In consideration of the telephonic conversa |
|
| March 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment Number 3 To FORM S-1/A REGISTRATION STATEMENT Under the Securities Act of 1933 ISMO TECH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 7378 46-4013793 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employe |
|
| February 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment Number 2 To FORM S-1/A REGISTRATION STATEMENT Under the Securities Act of 1933 ISMO TECH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 7378 46-4013793 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employe |
|
| February 28, 2014 |
Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 Weinberg & Baer LLC 115 Sudbrook Lane, Baltimore, MD 21208 Phone (410) 702-5660 Mr. |
|
| February 28, 2014 |
February 28, 2014 To: Barbara C. Jacobs, Assistant Director Or Jeff Kauten, Attorney-Advisor United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: ISMO Tech Solutions, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed February 11, 2014 File No.: 333-193328 Dear Ms. Jacobs: ISMO Tech Solutions, Inc., a Nevada corp |
|
| February 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment Number 1 To FORM S-1/A REGISTRATION STATEMENT Under the Securities Act of 1933 ISMO TECH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 7378 46-4013793 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employe |
